The basolateral amygdala is a nodal structure within a distributed and interconnected network that regulates anxiety states and anxiety-related behavior. Administration of multiple anxiogenic drugs increases cellular responses (i.e., increases c-Fos expression) in a subregion of the basolateral amygdala, but the neurochemical phenotypes of these cells are not known. The basolateral amygdala contains glutamatergic projection neurons and several populations of γ-aminobutyric acid-synthesizing (GABAergic) interneurons, including a population of parvalbumin (PV)-expressing GABAergic interneurons that co-express the excitatory 5-HT 2A receptor. The role for these PV-expressing GABAergic interneurons in anxiety-states is unclear. In this experiment we examined the effects of multiple anxiogenic drugs including the 5-HT 2C/2A receptor agonist m-chlorophenyl piperazine (mCPP), the adenosine receptor antagonist caffeine, the α 2 -adrenoreceptor antagonist yohimbine and the partial inverse agonist at the benzodiazepine allosteric site on the GABA A receptor, N-methyl-beta-carboline-3-carboxamide (FG-7142), on c-Fos expression in PV-immunoreactive (PV-ir) interneurons in subdivisions of the basolateral amygdala. All drugs with the exception of mCPP increased c-Fos expression in PV-ir neurons in the basolateral amygdaloid nucleus, anterior part (BLA). The numbers of c-Fos-immunoreactive (c-Fos-ir)/PV-ir GABAergic interneurons in the BLA were positively correlated with the numbers of c-Fos-ir serotonergic neurons in the mid-rostrocaudal dorsal raphe nucleus (DR) and with a measure of anxiety-related behavior. All four drugs increased c-Fos expression in non-PV-ir cells in most of the subdivisions of the basolateral amygdala that were sampled, compared with vehicleinjected controls. Together, these data suggest that the PV/5-HT 2A receptor expressing GABAergic interneurons in the basolateral amygdala are part of a DR-basolateral amygdala neuronal circuit modulating anxiety-states and anxiety-related behavior.
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Introduction
Anxiety is a complex emotional state associated with heightened physiological and behavioral arousal (Lowry et al., 2005; Lowry and Hale, 2010) . Although the mechanisms underlying the regulation of anxiety states and anxiety-related behaviors are not well understood, the physiological and behavioral arousal appears to be regulated by a distributed and interconnected system of forebrain and hindbrain structures that include the dorsal raphe nucleus (DR) and the basolateral amygdala (Hale et al., 2008a,b) . Consistent with this hypothesis, administration of multiple anxiogenic drugs with diverse pharmacological mechanisms increases c-Fos expression in serotonergic neurons in the DR (Abrams et al., 2005) and in cells within the basolateral amygdala (Singewald et al., 2003) , however the neurochemical phenotypes of the c-Fos-immunopositive cells in the basolateral amygdala are not known.
The basolateral amygdala is an important component of anxietyrelated neuronal circuitry (Davis et al., 1994) . We have reported that exposure of rats to a novel open-field arena increases c-Fos expression in the basolateral amygdala (Hale et al., 2006) and in a neuronal circuit projecting to the basolateral amygdala including the DR (Hale et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry 34 (2010 ) 1285 -1293 Abbreviations: 5-HT 2A , serotonin 2A receptor subtype; 5-HT 2C , serotonin 2C receptor subtype; ANOVA, analysis of variance; BLA, basolateral amygdaloid nucleus, anterior part; BLP, basolateral amygdaloid nucleus, posterior part; CRF, corticotropinreleasing factor; DAB, 3,3'-diaminobenzidine tetrahydrochloride; DR, dorsal raphe nucleus; DRC, dorsal raphe nucleus, caudal part; DRD, dorsal raphe nucleus, dorsal part; FG-7142, N-methyl-beta-carboline-3-carboxamide; GABA, γ-aminobutyric acid; LaDL, lateral amydaloid nucleus, dorsolateral part; LaVL, lateral amydaloid nucleus, ventrolateral part; LaVM, lateral amydaloid nucleus, ventromedial part; mCPP, mchlorophenyl piperazine; PB, 0.1 M sodium phosphate buffer; PBS, 0.1 M phosphate buffered saline; PBST, 0.1 M phosphate buffered saline with 0.3% Triton X-100; PV, parvalbumin; SI, social interaction test; SNAMA, spontaneous non-ambulatory motor activity; Ucn 1, urocortin 1; Ucn 2, urocortin 2.
